Eli Lilly LLY Taltz — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's taltz — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's taltz — revenue?
- Eli Lilly (LLY) reported taltz — revenue of $733M in Q1 2026.
- How has Eli Lilly's taltz — revenue changed year-over-year?
- Eli Lilly's taltz — revenue decreased by 3.8% year-over-year, from $762M to $733M.
- What is the long-term trend for Eli Lilly's taltz — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's taltz — revenue has grown at a 12.6% compound annual growth rate (CAGR), from $2.21B to $3.56B.
- What does taltz — revenue mean?
- This metric represents the total gross sales generated from the Taltz product line, which is an immunology therapeutic used for treating plaque psoriasis and related conditions. It reflects the market adoption, pricing power, and competitive positioning of the drug within the broader autoimmune disease treatment landscape. Monitoring this revenue stream helps assess the product's lifecycle stage and its contribution to the company's overall immunology portfolio performance.